Lead Sponsor

Fondazione Telethon

Collaborators

Age

0 - 65 years

Sex

ALL

Healthy Volunteers

No

•Age: up to 65 years
•Diagnosis of WAS defined by genetic mutation and at least one of the following criteria:
•* Severe Wiskott-Aldrich Syndrome (WAS) gene mutation, defined by literature data (genotype/phenotype studies).;
•* Absent WASP expression, assessed by flow cytometry;
•* Severe clinical score (Zhu clinical score ≥ 3);
•No human leukocyte antigen (HLA)-identical related donor available for hematopoietic stem cells transplant (HSCT).

•End-organ dysfunction, severe active infection not responsive to treatment or other severe disease or clinical condition which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
•Malignant neoplasia (except local skin cancer) or a documented history of hereditary cancer syndrome.
•Myelodysplasia, cytogenetic alterations characteristic of myelodysplastic syndrome and acute myeloid leukaemia , or other serious haematological disorders
•Documented human immunodeficiency virus (HIV) infection
•Prior allogeneic hematopoietic stem cell transplantation, with evidence of residual cells of donor origin
•Symptomatic herpes zoster, not responsive to specific treatment
•Evidence of acute tuberculosis
•Acute or chronic stable Hepatitis B
•Presence of positive Hepatitis C RNA test result at screening
•Previous Gene Therapy

Related studies

NCT01852370 · Severe Combined Immunodeficiency (SCID), Immunodeficiency With Predominant T-cell Defect, Unspecified, and more

NCT01410825 · Wiskott-Aldrich Syndrome

NCT01515462 · Wiskott-Aldrich Syndrome (WAS)

NCT01529827 · Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, and more

NCT00909363 · Wiskott-Aldrich Syndrome, Thrombocytopenia, and more

A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects With Wiskott-Aldrich Syndrome